Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chugai Pharmaceutical Co. Ltd.

Division of Roche
www.chugai-pharm.co.jp

Latest From Chugai Pharmaceutical Co. Ltd.

Approval Positions Roxadustat As Japan HIF-PHI Pioneer

The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.

Japan Approvals

Digital Health Trends: Asia Catching Up But Hurdles Remain

Digital health initiatives are rapidly emerging in Asia amid robust innovation and rising R&D activities in the region, but there are still some hurdles to overcome. An executive from Pfizer talks to Scrip about some of the major trends, opportunities and challenges.

Asia Pacific South Korea

Second Launch For Rozlytrek, In Japan, But Sales Prospects Limited

Entrectinib becomes first tumor-agnostic drug to be launched in Japan, its second market globally after the US, but commercial prospects will be limited given the highly specific patient population.

Japan Cancer

Keeping Track: CDER Ties Monthly Novel Approval Record With Nourianz Green Light

The latest drug development news and highlights from our US FDA Performance Tracker. 

Approvals Drug Review
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register